- Home
- GDYN vs CTNM Comparison
GDYN vs CTNM Comparison
Compare GDYN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDYN | CTNM |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.5M | 550.7M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GDYN | CTNM |
|---|---|---|
| Price | $8.55 | $8.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $9.40 | ★ $22.14 |
| AVG Volume (30 Days) | 683.2K | ★ 1.3M |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 0.46 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $111,283,000.00 | N/A |
| Revenue This Year | $6.37 | N/A |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | $427.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.11 | $6.73 |
| 52 Week High | $10.21 | $17.79 |
Technical Indicators
Market Signals| Indicator | GDYN | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 33.68 |
| Support Level | $7.56 | N/A |
| Resistance Level | $8.72 | $13.72 |
| Average True Range (ATR) | 0.32 | 0.99 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 97.51 | 22.44 |
Price Performance
Historical ComparisonAbout GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.